A cost-effectiveness analysis of alternative approaches for long-term treatment of proximal venous thrombosis.
Recent data from randomized trials have provided a clear understanding of the effectiveness and safety of differing long-term anticoagulant therapies for proximal vein thrombosis. An issue that has not been addressed is their cost-effectiveness. We have performed a cost-effectiveness analysis to rank alternative approaches for long-term therapy. Less intense oral anticoagulant therapy using warfarin sodium is the most cost-effective approach and is preferred in the majority of patients.
D002170:Canada; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D005260:Female; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008134:Long-Term Care / Q000191:economics*; D008297:Male; D008875:Middle Aged; D009864:Ontario; D011897:Random Allocation; D012008:Recurrence; D013924:Thrombophlebitis / Q000150:complications / Q000188:drug therapy / Q000191:economics*; D014859:Warfarin / Q000008:administration & dosage / Q000627:therapeutic use*
D014859:Warfarin; D006493:Heparin